4D Molecular Therapeutics Inc., of Emeryville, Calif., which filed to raise up to $100 million in an IPO in September last year, has withdrawn its plans for the offering. It had applied to list its shares on Nasdaq under the ticker symbol DDDD.
Alx Oncology Holdings Inc., of Burlingame, Calif., which is developing therapies that block the CD47 checkpoint pathway, said it closed its IPO of 9.77 million shares, including the full exercise of the underwriters’ option to purchase up to 1.27 million additional shares, at $19 each. The gross proceeds were approximately $185.7 million. The company’s shares are trading on Nasdaq under the ticker symbol ALXO.
CASI Pharmaceuticals Inc., of Rockville, Md., priced a public offering of 20 million shares at $1.90 per share for gross proceeds of about $38 million. The underwriters will also be granted a 30-day option to purchase up 3 million additional shares. The net proceeds will be used for working capital and general corporate purposes.
Cytokinetics Inc., of South San Francisco, said it closed its underwritten public offering of 8.38 million shares at $24 each. The total number of shares sold included the exercise in full by the underwriters of their option to purchase up to 1.09 million additional shares. The gross proceeds raised were approximately $201.3 million. Oppenheimer & Co. Inc. is acting as the sole book-running manager, and Brookline Capital Markets, a division of Arcadia Securities LLC is acting as co-manager. Shares of CASI (NASDAQ:CASI) closed July 22 at $1.90, down 33 cents.
Eikonoklastes Therapeutics Inc., of Cincinnati, which is developing next-generation tissue factor immunotherapies for triple-negative breast cancer and several other diseases, said it closed an oversubscribed seed financing. The amount was not disclosed. The company’s L-ICON3 immune conjugate platform was discovered and engineered by scientific founder Zhiwei Hu, an early pioneer of tissue factor physiology, who has worked to leverage tissue factor as a highly specific and highly selective target for therapy. The seed round will enable the company to complete a confirmatory in vivo I.V. efficacy study, to study I.V. pharmacokinetics, and to initiate manufacturing scaleup.
Genocea Biosciences Inc., of Cambridge, Mass., said it entered a private placement led by an undisclosed U.S. public investment fund specializing in life sciences as well as certain existing and new investors providing for the purchase of up to approximately $80 million of its common stock and warrants to purchase shares. The company will offer 21.4 million shares and 12.2 million prefunded warrants to purchase common stock, along with accompanying warrants to purchase one share for each share or prefunded warrant purchased by an investor. The warrants will have an exercise price of $2.25 per share and a four-year term. The company intends to use the net proceeds to fund continued clinical and program development of its neoantigen vaccine, GEN-009, and its neoantigen cell therapy, GEN-011, as well as for working capital and other general corporate purposes.
GT Biopharma Inc., of Los Angeles, said it completed a private offering resulting in aggregate gross proceeds of approximately $5.6 million. The company is conducting a phase I/II trial for GTB-3550 in patients with CD33-positive leukemia for acute myeloid leukemia, and is also studying myelodysplastic syndrome, and other CD33-positive hematopoietic malignancies along with other solid tumor candidates.
Kiniksa Pharmaceuticals Ltd., of Hamilton, Bermuda, said it priced its public offering of 5.95 million class A common shares at $21 each together with a concurrent private placement of 1.42 million class A1 common shares that collectively generated approximately $155 million. In addition, the company has granted the underwriters a 30-day option to purchase up to 892,857 additional class A common shares at the public offering price. The net proceeds will be used to advance the development of its product candidates, to advance commercialization activities and to fund other research and development activities as well as for working capital and general corporate purposes.
Olema Oncology Inc., of San Francisco, said it closed an oversubscribed $54 million series B financing that will be used to advance OP-1250, its lead program in breast cancer, into phase I/II development and expand ongoing research and development activities. The trial will evaluate OP-1250 as a single agent in women with estrogen receptor-positive, HER2-negative, recurrent, locally advanced or metastatic breast cancer, followed by studies of OP-1250 in combination with other targeted breast cancer therapies. The financing was co-led by BVF Partners LP, Logos Capital and Janus Henderson Investors, with participation from new investors Cormorant Asset Management, RA Capital Management, Wellington Management Company, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Foresite Capital.
Resverlogix Corp., of Calgary, Alberta, said the maturity date of its $12 million 10% secured convertible debenture, and payment of associated accrued interest, has been extended by one year from Sept. 26, 2020, to Sept. 26, 2021. In connection with the extension, the holder, a wholly owned subsidiary of ORI Star Fund LP, received 600,000 warrants exercisable until Dec. 31, 2024, at CA74 cents (US55 cents) per share.
Vesigen Therapeutics Inc., of Cambridge, Mass., said Leaps by Bayer and Morningside Ventures led its series A financing that raised $28.5 million. Also participating in the round was Linden Lake Ventures and Alexandria Venture Investments. The company is developing drugs based on the ARRDC1-mediated microvesicles (ARMMs) technology, a class of fusogenic extracellular vesicles that nature evolved to package and deliver communication signals between cells and tissues. ARMMs possess unique properties, making them better suited for producing and delivering therapeutic agents, the company said. Vesigen and its scientific founders have demonstrated that a wide range of therapeutic payloads can be packaged in ARMMs, including RNA, protein and gene-editing systems, and functionally delivered intracellularly in vitro and in vivo.